Wantai Biological's Clinical Trial Application for RSV Vaccine Receives Regulatory Acceptance

Stock News07-20

Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SSE: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has received a formal acceptance notice from the National Medical Products Administration (NMPA).

The application for clinical trials of its "Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)" has been accepted for review by the regulatory authority.

The acceptance of this clinical trial application marks a significant milestone in the company's innovative vaccine development pipeline.

This product represents a key strategic initiative, building upon the company's existing expertise in core antigen design, recombinant protein expression, and formulation development specifically targeting respiratory syncytial virus (RSV).

The development involves further clinical exploration and optimization across different formulation technology pathways.

This step will facilitate a systematic evaluation of the candidate product's immunogenicity, safety, tolerability, and broader applicability in the target population during the early clinical stages.

The data gathered will provide a crucial foundation for making informed decisions on subsequent product development pathways and for optimizing future clinical trial protocols.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164667387?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164667387","market":"us","top_or_hot":-1,"title":"Wantai Biological's Clinical Trial Application for RSV Vaccine Receives Regulatory Acceptance","media":"Stock News","content":"<p>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (<b>SSE: 603392</b>) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has received a formal acceptance notice from the National Medical Products Administration (NMPA).<br><br>The application for clinical trials of its \"Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)\" has been accepted for review by the regulatory authority.<br><br>The acceptance of this clinical trial application marks a significant milestone in the company's innovative vaccine development pipeline.<br><br>This product represents a key strategic initiative, building upon the company's existing expertise in core antigen design, recombinant protein expression, and formulation development specifically targeting respiratory syncytial virus (RSV).<br><br>The development involves further clinical exploration and optimization across different formulation technology pathways.<br><br>This step will facilitate a systematic evaluation of the candidate product's immunogenicity, safety, tolerability, and broader applicability in the target population during the early clinical stages.<br><br>The data gathered will provide a crucial foundation for making informed decisions on subsequent product development pathways and for optimizing future clinical trial protocols.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wantai Biological's Clinical Trial Application for RSV Vaccine Receives Regulatory Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWantai Biological's Clinical Trial Application for RSV Vaccine Receives Regulatory Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (<b>SSE: 603392</b>) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has received a formal acceptance notice from the National Medical Products Administration (NMPA).<br><br>The application for clinical trials of its \"Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)\" has been accepted for review by the regulatory authority.<br><br>The acceptance of this clinical trial application marks a significant milestone in the company's innovative vaccine development pipeline.<br><br>This product represents a key strategic initiative, building upon the company's existing expertise in core antigen design, recombinant protein expression, and formulation development specifically targeting respiratory syncytial virus (RSV).<br><br>The development involves further clinical exploration and optimization across different formulation technology pathways.<br><br>This step will facilitate a systematic evaluation of the candidate product's immunogenicity, safety, tolerability, and broader applicability in the target population during the early clinical stages.<br><br>The data gathered will provide a crucial foundation for making informed decisions on subsequent product development pathways and for optimizing future clinical trial protocols.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1164667387","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164667387","pubTimestamp":1784540068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SSE: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has received a formal acceptance notice...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","603392":"万泰生物","BK0239":"医药制造","BMED":"iShares Health Innovation Active ETF","LU1981816686.USD":"EASTSPRING INV ASIAN MULTI FACTOR EQUITY \"A\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","09633":"农夫山泉","BK1200":"软饮料","BK1589":"北水核心资产"},"translate_title":"万泰生物RSV疫苗临床试验申请获监管部门受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"603392":1,"09633":1,"IBBQ":1,"BMED":1},"content_text":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SSE: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has received a formal acceptance notice from the National Medical Products Administration (NMPA).The application for clinical trials of its \"Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)\" has been accepted for review by the regulatory authority.The acceptance of this clinical trial application marks a significant milestone in the company's innovative vaccine development pipeline.This product represents a key strategic initiative, building upon the company's existing expertise in core antigen design, recombinant protein expression, and formulation development specifically targeting respiratory syncytial virus (RSV).The development involves further clinical exploration and optimization across different formulation technology pathways.This step will facilitate a systematic evaluation of the candidate product's immunogenicity, safety, tolerability, and broader applicability in the target population during the early clinical stages.The data gathered will provide a crucial foundation for making informed decisions on subsequent product development pathways and for optimizing future clinical trial protocols.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164667387","isCrawlerRequest":true}